Latest news with #Cyanotech
Yahoo
24-06-2025
- Business
- Yahoo
Cyanotech Corp (CYAN) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Financial ...
Release Date: June 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Cyanotech Corp (CYAN) reported a 5% growth in net sales for the fiscal year 2025. The company achieved an 11% improvement in expenses due to efficiencies in production and tight inventory management. Bulk spirulina and Bulkasa Xanthin sales grew significantly by 53% and 74% respectively. Gross profit margin improved to 28.4% for the fiscal year, up from 25.8% the previous year. Operating loss for the fiscal year decreased to $2.5 million from $4.6 million in the prior year. Net loss for the fiscal year was $3.2 million, although reduced from the previous year's $5.3 million. Cash reserves decreased to $257,000 at the end of the fiscal year, down from $707,000 the previous year. Working capital also declined to $302,000 from $2 million at the end of fiscal year 2024. Package sales declined by about 5%, offsetting some of the gains in bulk product sales. Despite improvements, the company still reported a net loss per diluted share of $0.45 for the fiscal year. Warning! GuruFocus has detected 6 Warning Signs with CYAN. Q: Can you provide an overview of Cyanotech Corp's financial performance for the fourth quarter and fiscal year 2025? A: Jennifer Rogerson, CFO, reported that net sales for the fourth quarter were $6.3 million, up from $6 million the previous year, marking a 5.5% increase. For the fiscal year, total sales reached $24.2 million, a 5% increase from $23.1 million last year. The gross profit for the fourth quarter was $1.7 million with a margin of 27.7%, compared to $675,000 and 11.3% in the previous year. The fiscal year gross profit was $6.9 million with a margin of 28.4%, up from $5.9 million and 25.8% last year. The operating loss for the fourth quarter was $442,000, significantly reduced from $1.9 million the previous year. The fiscal year operating loss was $2.5 million, down from $4.6 million in 2024. The net loss for the quarter was $627,000 or $0.09 per diluted share, compared to $2.1 million or $0.30 per share last year. The full-year net loss was $3.2 million or $0.45 per share, compared to $5.3 million or $0.81 per share last year. The company ended the fiscal year with $257,000 in cash and $302,000 in working capital, down from $707,000 and $2 million, respectively, at the end of 2024. Q: What were the key factors contributing to the financial results? A: Matt Custer, CEO, highlighted that the 5% growth in net sales was driven by efficiencies in production and tight inventory management, which also contributed to an 11% improvement in expenses. The product mix shifted, with bulk spirulina and Bulkasa Xanthin sales growing by 53% and 74%, respectively, although there was a 5% decline in package sales. Strategic initiatives, including hiring a head of sales to expand retail channels, were also significant contributors. Q: How did Cyanotech Corp manage its inventory and cash flow? A: Matt Custer, CEO, stated that the company focused on balancing inventory levels to meet demand while being conservative with cash management. This approach was part of their strategic initiatives to expand market awareness and manage financial resources effectively. Q: What are the future projections and strategic plans for Cyanotech Corp? A: Matt Custer, CEO, mentioned that the company is looking forward to the next fiscal year with a focus on managing inventory levels to meet heightened demand. They plan to continue expanding market awareness and retail channel expansion, building on the strategic initiatives implemented this year. Q: Were there any questions from analysts or investors during the call? A: Matt Custer, CEO, noted that there were no questions received during the earnings call. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Wire
20-06-2025
- Business
- Business Wire
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025
KAILUA KONA, Hawaii--(BUSINESS WIRE)-- Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: 'Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%.' 'Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. We are focused on staying flexible, managing expenses and strengthening our customer relationships to navigate these challenges.' 'While I am proud of this year's progress, we know there is more to do. Our priority continues to be driving awareness of our naturally farmed microalgae from our farm in Kona, Hawaii.' Fiscal Year 2025 Cyanotech reported net sales of $24,215,000 for fiscal 2025 compared to $23,071,000 in fiscal 2024, an increase of 5.0%. Gross profit was $6,876,000, with a gross profit margin of 28.4%, compared to gross profit of $5,945,000 and gross profit margin of 25.8%. The operating loss was $2,508,000 compared to an operating loss of $4,592,000. Net loss was $3,203,000 or $0.45 loss per share, compared to net loss of $5,267,000 or $0.81 earnings per share. Fourth Quarter Fiscal 2025 Cyanotech reported net sales of $6,300,000 for the fourth quarter of fiscal year 2025 compared to $5,970,000 in the fourth quarter of fiscal 2024, an increase of 5.5%. Gross profit was $1,742,000 with a gross profit margin of 27.7%, compared to gross profit of $675,000 and gross profit margin of 11.3% in the fourth quarter of fiscal 2024. Operating loss was $442,000 compared to operating loss of $1,903,000 in the fourth quarter of fiscal 2024. Net loss was $627,000, or $0.09 loss per share, compared to net loss of $2,081,000, or $0.30 loss per share in the fourth quarter of fiscal 2024. Please review the Company's Form 10-K for the period ended March 31, 2025 for more detailed information. — Cyanotech will host a broadcast at 8:00 PM ET on Monday, June 23, 2025, to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to questions@ before 12 p.m. ET on Monday, June 23, 2025. The Company will respond only to relevant questions relating to the Company's fourth quarter and fiscal 2025 financial performance and will not be accepting any questions or comments during the broadcast. To join the broadcast, please browse approximately five minutes prior to the start time. About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 40 years, produces BioAstin ® Hawaiian Astaxanthin ® and Hawaiian Spirulina Pacifica ®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company's mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech's BioAstin ® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise †. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity †. All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe ('GRAS') for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the Food and Drug Administration. Visit for more information. † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Expand 'Safe Harbor ' Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, availability of financing, and our ability to continue as a going concern, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company's annual Form 10-K filings with the Securities and Exchange Commission. Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company's Form 10-K for the fiscal year ended March 31, 2025, which can be found on the Cyanotech website ( under Investors>Investor Filings upon filing. As such the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company's annual Form 10-K filings with the Securities and Exchange Commission. March 31, 2025 2024 (in thousands, except share data) ASSETS Current assets: Cash $ 257 $ 707 Accounts receivable, net of allowance for credit losses of $16 in 2025 and $11 in 2024 1,953 2,102 Inventories 7,788 7,313 Prepaid expenses and other current assets 547 469 Total current assets 10,545 10,591 Equipment and leasehold improvements, net 8,927 10,109 Operating lease right-of-use assets, net 3,902 4,284 Other assets 116 128 Total assets $ 23,490 $ 25,112 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,217 $ 1,439 Accrued expenses 715 757 Customer deposits 110 198 Operating lease obligations, current portion 555 530 Short term debt – bank 760 1,240 Line of credit – related party 3,000 1,250 Current maturities of long-term debt 2,886 3,140 Total current liabilities 10,243 8,554 Long-term debt – related party 1,000 1,000 Long-term operating lease obligations 3,363 3,744 Total liabilities 14,606 13,298 Commitments and contingencies Stockholders' equity: Preferred stock of $0.01 par value, 10,000,000 shares authorized; no shares issued and outstanding — — Common stock of $0.02 par value, 50,000,000 shares authorized; 7,199,908 shares at March 31, 2025 and 6,947,246 shares at March 31, 2024 issued and outstanding 144 139 Additional paid-in capital 34,844 34,576 Accumulated deficit (26,104 ) (22,901 ) Total stockholders' equity 8,884 11,814 Total liabilities and stockholders' equity $ 23,490 $ 25,112 Expand CYANOTECH CORPORATION Fiscal years ended March 31, 2025 2024 (in thousands) Net sales $ 24,215 $ 23,071 Cost of sales 17,339 17,126 Gross profit 6,876 5,945 Operating expenses: General and administrative 4,397 4,464 Sales and marketing 4,538 5,384 Research and development 449 689 Total operating expense 9,384 10,537 Loss from operations (2,508 ) (4,592 ) Other income (expense): Interest expense, net (687 ) (668 ) Loss before income tax expense (3,195 ) (5,260 ) Income tax expense (8 ) (7 ) Net loss $ (3,203 ) $ (5,267 ) Net loss per share: Basic and diluted $ (0.45 ) $ (0.81 ) Shares used in calculation of net loss per share: Basic and diluted 7,071 6,531 Expand
Yahoo
19-06-2025
- Health
- Yahoo
The Sun's Out. So Is the Secret to UV and Sun Support from Within.
How One Hawaiian Microalgae Farm Is Advancing Sun Care with BioAstin® Hawaiian Astaxanthin® KAILUA-KONA, Hawaii, June 19, 2025--(BUSINESS WIRE)--A new conversation in sun care is emerging — one that goes beyond the surface and into the science of supporting skin from within with microalgae. Nutrex Hawaii, a wholly owned subsidiary of Cyanotech Corporation and producer of BioAstin Hawaiian Astaxanthin, is leading that evolution with more than 40 years of natural microalgae cultivation, research, and innovation on Hawaii's Kona Coast. "For years, public health guidance has focused on external protection — sunscreen, shade, hats, protective clothing, and sunglasses. That's smart and we agree. Everyone on our Hawaiian farm follows these practices," said Collette Kakuk, Chief Strategic Officer at Nutrex Hawaii. "But science has evolved — and so has our understanding of skin support from within." The Science Behind the Shield. BioAstin Hawaiian Astaxanthin is one of nature's most powerful antioxidants and works in two ways to help protect skin under the sun: Neutralizes UV-induced free radicals, supporting healthy inflammation response, collagen integrity, and skin elasticity Accumulates in the skin's layers, embedding in cell membranes to deliver continuous, inside-out defense before damage begins With only 6–12mg daily (one small softgel), BioAstin® Hawaiian Astaxanthin® builds resilience and provides antioxidant support from within ☨ after about 3 to 4 weeks. Not a Sunscreen Replacement — A Sun Care Reinforcement Skin cancer is on the rise globally, with the United States consistently ranking among the highest reported cases. According to National Cancer Institute estimates, there were 100,640 new cases of skin melanomas and 8,290 related deaths in the United States in 2024. The American Academy of Dermatology Association estimates that one in five Americans will develop skin cancer in their lifetime. Finally, according to the Skin Cancer Foundation, about 90 percent of nonmelanoma skin cancers are associated with exposure to ultraviolet (UV) radiation from the sun. The following have long been advocated for with regard to sun safety: Using broad-spectrum, reef-safe sunscreen Wearing a wide brimmed hat & protective clothing Wearing UV-blocking sunglasses Seeking shade during peak hours BioAstin® doesn't aim to replace these measures — but to reinforce them. "Internal support fills a critical gap in modern sun care," said Kakuk. "It's not a replacement for sunscreen, but a crucial internal layer of adjunctive UV and sun support for responsible sun care — especially given how sunscreen is used in the real world: it sweats off, washes off, gets missed in spots, or isn't reapplied as often as it should be." More Than Skin Deep: Full-Body Support for Life Under the Sun As an antioxidant 6,000x stronger than Vitamin C — BioAstin® helps provide internal support against UV and sun exposure ☨ — it's also one of the rare natural antioxidants capable of crossing both the blood-brain and blood-retinal barriers, entering deep into the mitochondria, our cellular engines where energy is produced and oxidative damage is most critical. This extraordinary bioactivity supports a wide range of clinically documented benefits for full-body wellness, including eye, skin, joint, heart, and brain health ☨, as well as post-exercise recovery ☨ and cellular support ☨. "Here in Hawaii, we've long known BioAstin® provides powerful internal antioxidant support. From beach goers, lifeguards, surfers, and tourists to outdoor workers and healthy agers, we're proud to expand the sun care conversation with superior microalgae that supports the body in much the same way it functions in nature," said Kakuk. Nature's Blueprint for Sun Defense: Biomimicry in Action In the natural world, the freshwater microalga Haematococcus pluvialis faces harsh environmental stress, including intense UV radiation from the sun. To survive, it produces high levels of astaxanthin, a powerful red carotenoid antioxidant, to form a protective barrier against UV damage and oxidation. This same mechanism is what makes astaxanthin so extraordinary for humans. The way astaxanthin protects microalgae from UV-induced stress in nature is the same way it works within the human body — helping to support skin from within. It's a striking example of biomimicry, where nature's survival strategies are mirrored in how it functions in the body. "In nature, this unique microalgae survives intense UV stress by producing astaxanthin — a powerful antioxidant and striking example of biomimicry," said Dr. Gerry Cysewski, PhD, Founder and Chief Scientific Officer of Nutrex Hawaii. "I've spent my career studying and cultivating these remarkable organisms because of their unique biochemical properties and continually unfolding potential. Supporting our bodies under the sun with the same molecule nature uses to protect its own life forms isn't just smart science — it's common sense." BioAstin harnesses this biological brilliance with natural astaxanthin farm grown outdoors — never synthetic or bio-identical versions produced in labs under LED lights. BioAstin is cultivated in sustainable, open-air ponds on Hawaii's Kona Coast, where intense natural sunlight triggers the microalga's defense response to produce astaxanthin. A Legacy Rooted in Science, Sustainability, and Hawaii Nutrex Hawaii is one of Hawaii's longest-standing farm-based supplement brands, having sustainably cultivated microalgae on the Kona Coast for over 40 years. Every harvest is traceable, rigorously tested, and grown with care using sustainable aquaculture practices in one of the world's sunniest climates. See Where It's Grown – Video Link Fly over the Kona Hawaii Farm Navigate to About Nutrex Hawaii: For over 40 years, Nutrex Hawaii has sustainably cultivated microalgae to support health and wellness. Grown on a purpose-built 96-acre farm on the pristine Kona Coast of Hawaii, its flagship products—BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®—are trusted worldwide. Nutrex Hawaii products are distributed across the United States and internationally through natural and specialty retailers, healthcare professionals, and e-commerce platforms including and ☨These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. View source version on Contacts Press Contact: Collette Kakuk ckakuk@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
